

Cardiac Troponin “T” in Neonates with Severe and Moderate Persistent Pulmonary Hypertension

Thesis Submitted for Partial Fulfillment of Master Degree

In Pediatrics

By

Shaimaa Yakoot Abd Elatif Yousif

M.B.B.C.H 2006

Factuality of Medicine, Ain Shams University

Supervised by

Prof. Dr. Tarek Mohy El-Gammasy

Assistant professor of pediatrics

Factuality of medicine

Ain Shams University

Prof. Dr. Omneya Ibrahim Youssef

Assistant professor of pediatrics

Factuality of Medicine

Ain Shams University

Dr. Noha Refaat Mohamed

Lecturer of clinical and chemical pathology

Factuality of Medicine

Ain Shames University

Factuality of medicine

Ain Shams University

(2014)



Acknowledgment

First of all, thanks to **Allah** the most merciful for guiding me through and giving me strength to complete this work.

It is a pleasure to express my deepest thanks and profound respect to my honored professor, ***Prof. Dr. Tarek Mohey El _Gammasy***, Ass. Professor of Pediatrics, Faculty of Medicine, Ain Shams University, for his continuous encouragement, and valuable supervision and guidance throughout this work. It has been an honor and a privilege to work under his generous supervision.

I am also deeply grateful and would like to express my sincere thanks and gratitude to ***Prof. Dr. Omneya Ibrahim Youssef***, Ass. Professor of Pediatrics, Faculty of Medicine, Ain Shams University, for her kind support, help, careful supervision and her continuous guidance.

Also, I wish to express my deep gratitude to ***Dr. Noha Refaat Mohamed***, Lecturer of clinical and chemical pathology, Faculty of Medicine, Ain Shams University, for her kind support, help, careful supervision and her continuous guidance.

No words could adequately express my deep appreciation to ***my family***, especially ***my mother*** for her continuous support and guidance. I shall remain indebted to her all my life.

Also special thanks to my patients, wishing them a happy and healthy life.



Contents

Content	Page
Acknowledgment	I
List of abbreviations	II – V
List of tables	VI – VIII
List of figures	IX – XII
Introduction	1-2
Aim of the work	3
Review of literature	4-41
Chapter (1): Persistent Pulmonary hypertension of the newborn	(4-34)
Chapter (2): Cardiac affection in Persistent Pulmonary Hypertension of the Newborn	(35-37)
Chapter (3): Cardiac Troponin T (cTnT)	(38-41)
Subjects and methods	42-56
Results	57-86
Discussion	87-100
Summary	101-106
Conclusion	107
Recommendations	108
References	109-132
Arabic summary	133-136



List of Tables

Table	Title	Page
1	Distribution of elecsys cTnT healthy newborns with respect to sex	40
2	Apgar score	44
3	Normal blood pressure by day of life in 406 healthy term newborns	46
4	Mean values of Gestational age, Body weight and age at cTnT sampling	57
5	Descriptive data of studied groups	58
6	Comparison between studied groups as regards Apgar score at 1 and 5 min.	59
7	Vital signs in both studied group	60
8	Cardiac examination finding in patients group	62
9	Pulse oximetry (sO ₂) findings in Patients	63
10	ABGs findings in patients group	64
11	Oxygen tension (PaO ₂) findings in patients group (gpI)	65
12	Chest X-ray findings in Patients group (gpI)	66
13	Oxygen Therapy in patients group (gpI)	67
14	Comparison between patients and control as regards M-Mode echocardiographic data	68
15	Frequency of Extra-pulmonary shunt in patients	70



16	Right and Left Preejection period /ejection time in studied groups	71
17	Comparison between studied groups as regards global left ventricular function by Tissue Doppler Imaging (TDI)	72
18	Comparison between studied groups as regards global Right ventricular function by Tissue Doppler Imaging (TDI)	73
19	Myocardial performance indices in both studied groups	74
20	Regional Right Ventricular Strain and Strain Rate (SR) in studied groups	75
21	Comparison between patients and control groups as regards cTnT levels	76
22	Comparison between ventilated and non-ventilated patients as regards cTnT	77
23	Comparison between patients who died and improved as regarding cTnT levels	78
24	Correlation between ABG and cTnT levels in patients group	79
25	Correlation between Echocardiographic findings in Patients and cTnT level in (gpI)	80
26	Correlation between RV and LV PEP/ET and cTnT levels in studied patients (gpI)	81
27	Correlation between Global LV function by TDI with cTnT level in Patients group (gpI)	82
28	Correlation between Global RV function by	83



	TDI and cTnT level in Patients group (gpI)	
29	Correlation between Tei index and cTnT levels in Patients group (gpI)	86
30	Correlation between cTnT levels and Regional Strain Rate mid in patients (gpI)	86



List of Figures

Figure	Title	Page
1	NO/cGMP pathway	6
2	Cardiopulmonary interactions in persistent pulmonary hypertension of the newborn.	8
3	Role of nitric oxide (NO) and prostacyclin (PGI ₂) signaling pathways in the regulation of pulmonary vascular tone and mechanism of action of different pharmacologic agents.	27
4	Classic veno-arterial extracorporeal membrane oxygenation	32
5	Molecular arrangement of troponin (Tn), tropomyosin (Tm), and actin in the skeletal muscle thin filament.	38
6	The new Ballard scoring system	45
7	GE Vivid I Ultrasound System	48
8	Measurements of pre-ejectional period and left ventricular ejection time.	50
9	The velocity spectrum of the wall motion assessed by pulsed wave Doppler tissue echocardiography	51
10	Measurement of strain and strain rate	52
11	Tei index by Tissue Doppler imaging	52
12	Mean values of GA, age of cTnT sampling and body weight.	57



13	Mode of delivery among Patients and control groups.	58
14	Comparison of Apgar score at 1 and 5 min between both studied groups.	59
15	Mean blood pressure (BP) in patients and control groups.	60
16	Mean Heart rate (HR) in patients and control groups.	61
17	Mean Respiratory rate (RR) in patients and control groups.	61
18	Cardiac examination finding in patient groups.	62
19	ABGs findings in patients group (gpI).	64
20	Percentage of PaO ₂ findings in patients group	65
21	Chest X-Ray findings on day of admission in patients group.	66
22	Need for ventilation in the Patients group.	67
23	mean values of M- mode data in both studied groups (AOR, IVS, LAD, LVEDD, RVDD, and PWT)	68
24	EF% in studied groups.	69
25	EPASP in studied groups.	69
26	Percentage of PDA in Patients group.	70
27	RV and LV PEP/ET in studied groups.	71
28	LV Tissue Doppler data in studied groups.	72



29	RV Tissue Doppler data in studied groups.	73
30	Tei index of RV & LV in both studied groups.	74
31	Right ventricular systolic strain and strain rate in gpI neonates.	75
32	Mean values of cTnT in Patients and control groups.	76
33	Mean levels of cTnT in ventilated and non-ventilated gpI.	77
34	Fate of patients group (gpI).	78
35	Correlation between levels of cTnT and sO ₂ , Po ₂ , and Pco ₂ in Patients.	79
36	Correlation between levels of cTnT and Hco ₃ , BE, and PH in Patients.	80
37	Correlation between levels of cTnT levels and RVDD of Patients.	81
38	Correlation between levels of cTnT levels and PDA diameter of Patients.	82
39	Correlation between levels of cTnT levels and EPAP of Patients group.	82
40	Correlation between cTnT levels and RV and LV (PEP/ET) in Patients.	83
41	Correlation between levels of cTnT and LV S _m , E _m , and E _m /A _m in Patients.	84
42	Correlation between levels of cTnT and E _T , S _T and E _T /A _T ratio in Patients.	85



43	Correlation between levels of cTnT and RV Strain Rate (Mid) in studied Patients.	87
-----------	-----------------------------------------------------------------------------------------	-----------



List of abbreviations

<i>2D</i>	Two dimensions
<i>ACD</i>	Alveolar Capillary Dysplasia
<i>A_m</i>	Peak mitral annular late diastolic velocity
<i>AOR</i>	Ascending aortic diameter
<i>A_T</i>	Peak tricuspid annular late diastolic velocity
<i>BPD</i>	bronchopulmonary dysplasia
<i>Bpm</i>	Beat per minute
<i>BW</i>	body weight
<i>C.S</i>	cesarean section
<i>Ca⁺²</i>	Calcium
<i>CCHD</i>	Cyanotic congenital heart disease
<i>CDH</i>	Congenital diaphragmatic hernia
<i>cGMP</i>	cyclic guanosine monophosphate
<i>CLD</i>	Chronic Lung Disease
<i>cPAP</i>	continuous positive airway pressure
<i>cTnT</i>	Cardiac troponin T
<i>DM</i>	Diabetes Mellitus
<i>DNA</i>	deoxyribonucleic acid
<i>ECMO</i>	extra corporeal membrane oxygenation



<i>ECs</i>	Endothelial cells
<i>E_m</i>	Peak mitral annular early diastolic velocity
<i>eNOS</i>	endothelial nitric oxide synthase
<i>E_T</i>	Peak tricuspid annular early diastolic velocity
<i>ET</i>	Ejection time
<i>ET-1</i>	endothelin-1
<i>FO</i>	foramen ovale
<i>GA</i>	gestational age
<i>GMP</i>	guanosine monophosphate
<i>H₂O₂</i>	hydrogen peroxide
<i>HFOV</i>	High Frequency Oscillatory Ventilation
<i>HNT</i>	Hypertension
<i>HS</i>	Highly significant
<i>ICT</i>	Isovolumetric contraction time
<i>iNO</i>	Inhaled nitric oxide
<i>IRT</i>	Isovolumetric relaxation time
<i>K⁺</i>	Potassium
<i>LAD</i>	Left atrium diameter
<i>LV</i>	left ventricular
<i>LVEDD</i>	Left ventricular end diastolic diameter
<i>MAS</i>	Meconium aspiration syndrome



<i>MgSO₄</i>	Magnesium sulphate
<i>MPI</i>	Myocardial performance index
<i>NADPH</i>	Nicotinamide adenine dinucleotide phosphate
<i>NICU</i>	Neonatal intensive care unit
<i>NO</i>	nitric oxide
<i>NOS</i>	nitric oxide synthase
<i>NS</i>	non-significant
<i>NSAIDs</i>	Non-steroidal anti-inflammatory drugs
<i>NVD</i>	Normal vaginal delivery
<i>PA</i>	pulmonary artery
<i>PAP</i>	pulmonary artery pressure
<i>PDA</i>	patent ductus arteriosus
<i>PDA</i>	Patent ductus arteriosus
<i>PDE</i>	Phosphodiesterase
<i>PEEP</i>	<i>Positive end-expiratory pressure</i>
<i>PEP</i>	Pre-ejection period
<i>PFO</i>	Patent foramen ovale
<i>PG</i>	Prostaglandin
<i>PH</i>	Pulmonary Hypertension
<i>PIP</i>	Peak <i>inspiratory pressure</i>
<i>PO₂</i>	oxygen pressure



<i>PPHN</i>	Persistent pulmonary hypertension of the newborn
<i>PVR</i>	pulmonary vascular resistance
<i>PWT</i>	Posterior wall thickness
<i>RAP</i>	Right atrium pressure
<i>RCTs</i>	A randomised controlled trials
<i>RDS</i>	Respiratory Distress Syndrome
<i>rhSOD</i>	recombinant human superoxide dismutase
<i>ROP</i>	retinopathy of prematurity
<i>RV</i>	right ventricular
<i>RVDD</i>	Right ventricular diastolic diameter
<i>RVPO</i>	Right ventricular pressure overload
<i>S</i>	Significant
<i>S₂</i>	Second heart sound
<i>S_m</i>	Peak mitral annular systolic motion velocity
<i>SMC</i>	smooth muscle cell
<i>SOD</i>	superoxide dismutase
<i>SPAP</i>	systolic pulmonary arterial pressure
<i>SP-B</i>	surfactant protein B
<i>SR</i>	Strain rate
<i>SRI</i>	serotonin-reuptake inhibitors
<i>SSRI</i>	selective serotonin reuptake inhibitors



<i>S_T</i>	Peak tricuspid annular systolic motion velocity
<i>SVR</i>	systemic vascular resistance
<i>TRVmax</i>	peak velocity of a tricuspid regurgitant jet
<i>VOCC</i>	voltage operated calcium channels
<i>wks</i>	Weeks